Harnessing the power of the immune system to fight cancer through research into cancer immune surveillance and chemo/immunotherapy, defining key cells and molecules that can elicit an effective response to tumours.

The ability of tumour cells to reprogram key metabolic pathways to facilitate tumorigenesis and metastasis is now recognised as one of the hallmarks of cancer.

The Cancer Therapeutics Program aims to integrate various basic research activities, platform technologies and pre-clinical model systems available within Peter Mac to discover, develop, characterise and refine novel cancer therapeutics for clinical use for solid tumours.

The Computational Biology Program uses mathematics, statistics and computing to generate new discoveries in cancer. We develop new models, algorithms and software tools, and apply these to make sense of cancer data. This includes whole genome, exome, transcriptome and epigenome sequencing data.

The Peter Mac Gastrointestinal Cancer Program provides a focus for clinical, preclinical, and basic science research across all cancers of the gastrointestinal tract (including oesophageal, gastric, colorectal and anal cancers).

The global effort to understand the molecular drivers of cancer is now coming to fruition with the identification of specific genomic events that affect signalling through key oncogenic pathways.

The primary focus of the Organogenesis & Cancer Program is to investigate the process of organ development and how failure of organogenesis contributes to cancer...

The Prostate Cancer Program is new to Peter Mac, and aims to answer significant questions that arise at diagnosis and during treatment of men with prostate cancer.

The Translational Haematology Program contains a diverse set of laboratories that focus on understanding the molecular pathogenesis of a range of haematological malignancies.

The program is interested in understanding the key role played by non-malignant cells within the tumour microenvironment, which includes stromal cells, blood vascular endothelial cells, lymphatic endothelial cells and immune cells.

Peter Mac is committed to linking patient care with cancer research. Our clinician researchers take their observations from the clinic and plan their research directions with patients in mind.